Jay Skyler, MD
Fellowship: Duke University Medical Center.
Residency: Duke University Medical Center.
MD: Jefferson Medical College.
BS: Pennsylvania State University.
Jay S. Skyler, MD, MACP is a 1969 graduate of Jefferson Medical College. He did postgraduate training at Duke University and NIH. He currently is Professor of Medicine, Pediatrics, and Psychology in the Division of Endocrinology, Diabetes, and Metabolism at the University of Miami. He is Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute, University of Miami, and Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado. For 22 years, Doctor Skyler was Study Chairman for the National Institutes of Health (NIH)-sponsored Diabetes Prevention Trial for T1DM (DPT-1) and its successor the NIH T1DM TrialNet Clinical Trials Study Group (TrialNet), clinical trials networks aimed at preventing T1D or interdicting the T1D disease process. Doctor Skyler had continuous grant support from NIH from 1979 to 2015. Doctor Skyler is closely involved with many scientific societies and has served as President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation; and Vice-President of the International Diabetes Federation. He was founding Editor-in-Chief of Diabetes Care (an American Diabetes Association publication with a current impact factor of 8.934) and founding Scientific Editor of the International Diabetes Monitor, and currently is Senior Editor of Diabetes Technology & Therapeutics. He is the recipient of the 1992 Banting Medal for Service from the American Diabetes Association, the 2014 Distinction in Endocrinology Award from the American College of Endocrinology, the 2015 Distinguished Faculty Scholar Award from the Faculty Senate of the University of Miami, the 2015 Mary Tyler Moore/S. Robert Levine Award for Distinction in Clinical Research from the Juvenile Diabetes Research Foundation, and the 2016 Distinguished Alumnus Award from Jefferson Medical College.
Dr Skyler's current research interest is in interdicting the type 1 diabetes disease process in human beings. To this end, he studied various interventions, including immune modulating drugs to stop the immune damage to beta cells and/or promote regulatory immunity; agents that enhance beta cell health; and approaches designed to tamper islet inflammation (either with pharmacologic agents and/or cellular therapeutic approaches).